278,865 Shares in RxSight, Inc. $RXST Acquired by Vitruvian Partners LLP

Vitruvian Partners LLP purchased a new stake in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 278,865 shares of the company's stock, valued at approximately $1,344,129. RxSight comprises approximately 0.0% of Vitruvian Partners LLP's portfolio, making the stock its 8th biggest holding. Vitruvian Partners LLP owned approximately 0.67% of RxSight as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. BlackRock Inc. acquired a new position in RxSight in the second quarter valued at approximately $27,910,000. Millennium Management LLC lifted its holdings in shares of RxSight by 130.6% during the third quarter. Millennium Management LLC now owns 2,193,062 shares of the company's stock valued at $19,716,000 after purchasing an additional 1,241,885 shares during the last quarter. Artisan Partners Limited Partnership raised its position in shares of RxSight by 23.0% during the fourth quarter. Artisan Partners Limited Partnership now owns 2,157,264 shares of the company's stock valued at $22,479,000 after buying an additional 403,581 shares during the last quarter. No Street GP LP raised its holdings in shares of RxSight by 35.4% in the third quarter. No Street GP LP now owns 1,625,000 shares of the company's stock valued at $14,609,000 after acquiring an additional 425,000 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of RxSight by 30.3% in the first quarter. Bank of America Corp DE now owns 1,210,039 shares of the company's stock worth $7,454,000 after buying an additional 281,426 shares during the last quarter. 78.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on RXST shares. Weiss Ratings cut shares of RxSight from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Thursday, June 11th. Jefferies Financial Group set a $6.50 price target on shares of RxSight in a report on Tuesday, July 7th. Stifel Nicolaus reduced their target price on RxSight from $8.00 to $7.00 and set a "hold" rating for the company in a report on Monday, August 10th. UBS Group upped their target price on RxSight from $5.50 to $6.30 and gave the company a "neutral" rating in a report on Thursday, August 6th. Finally, Wells Fargo & Company lowered their price objective on RxSight from $11.00 to $9.00 and set an "equal weight" rating on the stock in a research report on Thursday, May 7th. Two analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Reduce" and an average price target of $8.37.

RxSight Stock Performance

Shares of RxSight stock traded up $0.25 during trading on Friday, hitting $6.86. 223,522 shares of the stock were exchanged, compared to its average volume of 964,137. RxSight, Inc. has a 12 month low of $4.48 and a 12 month high of $13.22. The stock's fifty day moving average is $5.79 and its 200 day moving average is $6.38. The stock has a market cap of $285.33 million, a PE ratio of -6.07 and a beta of 1.13.

RxSight (NASDAQ:RXST - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.04. The company had revenue of $33.74 million during the quarter, compared to the consensus estimate of $32.55 million. RxSight had a negative net margin of 36.80% and a negative return on equity of 17.35%. Sell-side analysts anticipate that RxSight, Inc. will post -1.01 EPS for the current fiscal year.

RxSight Profile

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company's flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.